Harker Aquila

Biotechnology companies Pfizer, Moderna and AstraZeneca released first interim analysis reports from Phase 3 trials of their respective COVID-19 vaccines, all within the past month. The vaccines have efficacy rates of more than 95%, 94.5% and 70%, respectively.

3 COVID-19 vaccines move forward after promising Phase 3 clinical trial data

by Mark Hu and Sabrina Zhu December 2, 2020

Biotechnology companies Pfizer, Moderna and AstraZeneca released first interim analysis reports from Phase 3 trials of their respective COVID-19 vaccines, all within the past month. The vaccines have efficacy...

In the United States, three companies — Moderna, Pfizer and AstraZeneca — have been conducting Phase 3 trials for a coronavirus vaccine. Phase 3 trials are the last step before a vaccine can be approved, with 30,000 volunteers participating in a study testing the efficacy of each vaccine.

SARS-CoV-2 vaccines continue Phase 3 trials, testing

by Aditya Singhvi, Aquila Co-Managing Editor September 28, 2020

As the coronavirus pandemic continues to expand, scientists around the globe are racing to develop and test an effective vaccine that can be approved for widespread use. In the United States, three...

Load More Stories
Activate Search
The student news site of The Harker School.
astrazeneca